Adult patients with relapsed or refractory multiple myeloma, after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti‐CD38 monoclonal antibody. This evidence concerns the gene CD38 and AL amyloidosis.